<DOC>
	<DOCNO>NCT01625429</DOCNO>
	<brief_summary>This single-center , prospective , single arm phase II study evaluate efficacy safety nab-paclitaxel plus carboplatin ( trastuzumab HER-2 positive patient ) neoadjuvant therapy operable locally advanced breast cancer patient . The primary objective pCR . The secondary objective include ORR , 3-yr DFS , OS safety . The sample size 30 .</brief_summary>
	<brief_title>Neoadjuvant Study Nab-paclitaxel Plus Carboplatin Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female , 18 70 year old Life expectancy 12 month Breast MRI ultrasound confirmd tumor 3cm biopsy comfirned invasive breast caner stage IIIII ( inflammatory breast cancer exclude ) Not accompany malignancies（except control carcinoma situ cervix skin basalcell carcinoma） A normal bone marrow : absolute neutrophil count≥1.5*10E9/L , hemoglobin≥100g/L , PLT≥100*10E9/L Normal liver renal function : AST≤60U/L , total biliruin≤1.5*upper limit normal , serum creatinine≤110umol/L , urea nitrogen≤7.1mmol/L Normal blood coagulation function ECOG performance status 01 Willing coordinate punch biopsy treatment accept neoadjuvant therapy Women childproducing potential must agree use effective contraceptive method study , negative serum urine pregnancy test must obtain within 7 day prior administration drug Written inform consent For HER2 positive patient , HER2 status must determine ICH +++ FISH/CISH . For patient treat trastuzumb , LVEF≥55 % ultrasonic cardiogram MUGA scan Previous systematic local therapy include chemotherapy breast cancer Distant metastases breast cancer observe Concurrent uncontrolled lung disease , severe sepsis , active peptic ulcer requring treatment , blood coagulation disorder , serious uncontrolled diabetes , connective tissue disease bone marrow depression , unable tolerate neoadjuvant therapy relate treatment &gt; Grade 1 peripheral neuropathy cause reason History CHF , uncontrolled symptomatic angina , history arrhythmias myocardial infarction , poorly control hypertension ( systolic pressure &gt; 180mmHg diastlic pressure &gt; 100 mmHg ) Lactational gestational breast cancer Not willing accept punch biopsy treatment neoadjuvant therapy Psychopath reason would preclude compliane treatment Known serious allergy study drug excipients Participation another study require administration investigational drug biological agent present recently ( within last 30 day prior screen visit )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>